leadf
logo-loader
viewAcasti Pharma Inc

Acasti Pharma initiates review process to evaluate strategic alternatives to boost shareholder value

There are additional analyses of TRILOGY data underway for lead drug CaPre, a krill-oil derived prescription drug, aimed at treating high levels of triglycerides in the blood

Acasti Pharma Inc - Acasti Pharma initiates a review process to evaluate strategic alternatives to boost shareholder value
The Laval, Quebec-based biopharmaceutical innovator said that it has engaged Oppenheimer & Company as its financial advisor to assist in the process

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) announced on Tuesday that the company has initiated a formal process to “explore and evaluate” strategic alternatives “to enhance shareholder value.”

In a statement, the Laval, Quebec-based biopharmaceutical innovator said it has engaged Oppenheimer & Company Inc as its financial advisor to assist in the process.

“There can be no assurance of a successful outcome from these efforts, or of the form or timing of any such outcome,” the company said in a brief statement.

READ: Acasti Pharma reports results from Phase 3 TRILOGY 2 study of lead drug CaPre

The company made it clear that it “does not intend to make any further disclosures” regarding the strategic review process unless and until a specific course of action is approved by the company’s board.

Meanwhile, Acasti Pharma emphasized that along with its clinical advisors, it plans to “complete the full data analyses” as contemplated in the Statistical Analysis Plan for TRILOGY 2, including the secondary and exploratory endpoints, and “the pooling of the data from TRILOGY 1 and 2.”

Last month, Acasti Pharma released topline results from its Phase 3 TRILOGY 2 trial of lead drug CaPre that saw a 30.4% average reduction in triglyceride levels among all patients receiving CaPre, as compared to 30.5% in TRILOGY 1, and a 17.9% median reduction in triglyceride levels among patients receiving placebo at 12 weeks as compared to 27.5% in TRILOGY 1.

CaPre is a krill-oil derived prescription drug, aimed at treating hypertriglyceridemia, or high levels of triglycerides in the blood, which is known to contribute to heart disease.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: Acasti Pharma Inc

Price: 0.265 CAD

TSX-V:ACST
Market: TSX-V
Market Cap: $25.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 26/11/19

2 min read